Pheochromocytoma - Pipeline Insight, 2024

Pheochromocytoma - Pipeline Insight, 2024

DelveInsight’s, “Pheochromocytoma - Pipeline Insight, 2024,” report provides comprehensive insights about 8+ companies and 8+ pipeline drugs in Pheochromocytoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Pheochromocytoma Understanding

Pheochromocytoma: Overview

Pheochromocytoma is a rare tumor that usually starts in the cells of one of your adrenal glands. It results in the release of too much epinephrine and norepinephrine, hormones that control heart rate, metabolism, and blood pressure. Pheochromocytoma may occur as a single tumor or as more than one growth. It usually develops in the center (medulla) of one or both adrenal glands. Symptoms associated with pheochromocytomas include high blood pressure (hypertension), headaches, excessive sweating, and/or heart palpitations. In approximately 25 to 35 percent of cases, pheochromocytomas may be inherited as an autosomal dominant trait. Blood and urine analysis can confirm a diagnosis of pheochromocytoma by detecting elevated levels of catecholamines or its metabolites in the urine and blood (plasma). Phenoxybenzamine or a similar drug is generally given to stop hormone action. The most common surgical procedure for treating pheochromocytoma is laparoscopic adrenalectomy. Radiation therapy, in which radiation is used to target and destroy cancer cells, and certain combinations of anticancer drugs (chemotherapy) may also be used to treat individuals with malignant pheochromocytoma.

""Pheochromocytoma - Pipeline Insight, 2024"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Pheochromocytoma pipeline landscape is provided which includes the disease overview and Pheochromocytoma treatment guidelines. The assessment part of the report embraces, in depth Pheochromocytoma commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Pheochromocytoma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Pheochromocytoma R&D. The therapies under development are focused on novel approaches to treat/improve Pheochromocytoma.

Pheochromocytoma Emerging Drugs Chapters

This segment of the Pheochromocytoma report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Pheochromocytoma Emerging Drugs

• Sunitinib: Pfizer

Sunitinib is a novel oral multitargeted tyrosine kinase inhibitor with antitumor and antiangiogenic activities. Sunitinib is approved in first-line treatment for patients with advanced renal cell carcinoma (RCC) and for the treatment of patients with gastrointestinal stromal tumors (GIST) after disease progression or intolerance to imatinib mesylate therapy. The drug is in Phase II clinical studies for the treatment of Pheochromocytoma.

• Guadecitabine: Astex Pharmaceuticals

Guadecitabine is a next-generation DNA hypomethylating agent. Guadecitabine is rationally designed to be resistant to degradation by cytidine deaminase, prolonging the exposure of tumor cells to the active metabolite, decitabine, thus ensuring greater uptake of decitabine into the DNA of rapidly dividing cancer cells. Guadecitabine-mediated inhibition of DNA methylation upregulates tumor-associated antigens and may sensitize tumor cells to other anticancer agents, including immunotherapeutics, as well as resensitize resistant cancer cells to chemotherapeutics. The drug is in Phase II clinical evaluation for the treatment of Pheochromocytoma.

Further product details are provided in the report……..

Pheochromocytoma: Therapeutic Assessment

This segment of the report provides insights about the different Pheochromocytoma drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Pheochromocytoma

There are approx. 8+ key companies which are developing the therapies for Pheochromocytoma. The companies which have their Pheochromocytoma drug candidates in the most advanced stage, i.e. Preregistration include, Pfizer.

• Phases

DelveInsight’s report covers around 8+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Pheochromocytoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Parenteral
• Intravitreal
• Subretinal
• Topical
• Molecule Type

Products have been categorized under various Molecule types such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Pheochromocytoma: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Pheochromocytoma therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Pheochromocytoma drugs.

Pheochromocytoma Report Insights

• Pheochromocytoma Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Pheochromocytoma Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Pheochromocytoma drugs?
• How many Pheochromocytoma drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Pheochromocytoma?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Pheochromocytoma therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Pheochromocytoma and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Pfizer
• Exelixis
• Ipsen
• Genentech
• Astex Pharmaceuticals
• Advanced Accelerator Applications

Key Products

• Sunitinib
• Cabozantinib
• Atezolizumab
• Guadecitabine
• Lutetium-177 oxodotreotide